PL4371987T3 - Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 - Google Patents

Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1

Info

Publication number
PL4371987T3
PL4371987T3 PL24150846.4T PL24150846T PL4371987T3 PL 4371987 T3 PL4371987 T3 PL 4371987T3 PL 24150846 T PL24150846 T PL 24150846T PL 4371987 T3 PL4371987 T3 PL 4371987T3
Authority
PL
Poland
Prior art keywords
substituted
azabenzimidazole compounds
hpk1 inhibitors
hpk1
inhibitors
Prior art date
Application number
PL24150846.4T
Other languages
English (en)
Inventor
Gayatri BALAN
Mark J. Bartlett
Jayaraman Chandrasekhar
Julian A. Codelli
John H. Conway
Jennifer L. COSMAN
Rao V. KALLA
Zachary A. KASUN
Musong Kim
Seung H. Lee
Jennifer R. Lo
Jennifer A. Loyer-Drew
Scott A. Mitchell
Thao D. Perry
Gary B. Phillips
Patrick J. SALVO
Sundaramoorthi Swaminathan
Joshua J. Van Veldhuizen
Suet C. YEUNG
Jeff Zablocki
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4371987T3 publication Critical patent/PL4371987T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
PL24150846.4T 2018-10-31 2019-10-30 Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 PL4371987T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753339P 2018-10-31 2018-10-31
US201962868550P 2019-06-28 2019-06-28

Publications (1)

Publication Number Publication Date
PL4371987T3 true PL4371987T3 (pl) 2026-01-12

Family

ID=68771764

Family Applications (2)

Application Number Title Priority Date Filing Date
PL24150846.4T PL4371987T3 (pl) 2018-10-31 2019-10-30 Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
PL19813990.9T PL3873903T3 (pl) 2018-10-31 2019-10-30 Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19813990.9T PL3873903T3 (pl) 2018-10-31 2019-10-30 Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1

Country Status (31)

Country Link
US (3) US11203591B2 (pl)
EP (3) EP3873903B1 (pl)
JP (2) JP7460644B2 (pl)
KR (1) KR102650496B1 (pl)
CN (1) CN113227089B (pl)
AU (3) AU2019372046B2 (pl)
BR (1) BR112021008255A2 (pl)
CA (1) CA3117556A1 (pl)
CL (1) CL2021001132A1 (pl)
CO (1) CO2021005711A2 (pl)
CR (1) CR20210215A (pl)
DK (1) DK3873903T3 (pl)
DO (2) DOP2021000079A (pl)
ES (2) ES2979163T3 (pl)
FI (1) FI3873903T3 (pl)
HR (2) HRP20251388T1 (pl)
HU (1) HUE066750T2 (pl)
IL (1) IL282535B2 (pl)
LT (1) LT3873903T (pl)
MX (1) MX2021005047A (pl)
MY (1) MY205142A (pl)
PE (1) PE20211655A1 (pl)
PH (1) PH12021551019A1 (pl)
PL (2) PL4371987T3 (pl)
PT (1) PT3873903T (pl)
SG (1) SG11202103839UA (pl)
SI (1) SI3873903T1 (pl)
TW (2) TWI721623B (pl)
UA (1) UA126619C2 (pl)
WO (1) WO2020092621A1 (pl)
ZA (2) ZA202304921B (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
KR102658602B1 (ko) * 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
MX2022004370A (es) 2019-10-18 2022-05-06 Forty Seven Inc Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021095801A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬
JP7711068B2 (ja) 2019-12-24 2025-07-22 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
CN118930560A (zh) * 2020-05-06 2024-11-12 新锐思生物制药股份有限公司 造血祖细胞激酶的双功能降解剂及其治疗用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022258044A1 (zh) * 2021-06-11 2022-12-15 杭州中美华东制药有限公司 吡咯并吡啶酮类化合物及其制备方法和用途
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
EP4373817B1 (en) 2021-07-20 2025-05-21 Astrazeneca AB Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
CN115677681A (zh) * 2021-07-23 2023-02-03 上海挚盟医药科技有限公司 一种乙肝病毒核衣壳抑制剂的制备方法
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
JP2024543377A (ja) * 2021-11-10 2024-11-21 ニューリックス セラピューティクス，インコーポレイテッド 造血前駆体キナーゼの二官能性分解物質およびその治療的使用
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
EP4667056A1 (en) 2021-12-22 2025-12-24 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
LT4245756T (lt) 2022-03-17 2024-11-25 Gilead Sciences, Inc. Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4695260A1 (en) 2023-04-11 2026-02-18 Gilead Sciences, Inc. Kras modulating compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
AU2024300557A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (513)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
NZ514195A (en) 1999-03-17 2004-05-28 Astrazeneca Ab Amide derivatives
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7294635B2 (en) 2003-10-03 2007-11-13 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
DE602004025504D1 (de) 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US20050288502A1 (en) 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200745033A (en) 2005-09-14 2007-12-16 Dainippon Sumitomo Pharma Co Oxindole derivative as feeding control agent
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
ES2437871T3 (es) 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
RU2009128693A (ru) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Замещенные производные изохинолина и изохинолинона
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
WO2008124323A1 (en) 2007-04-03 2008-10-16 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
JP5395068B2 (ja) 2007-06-29 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド トール様受容体７の調節物質としてのプリン誘導体およびその使用
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
EP2020405A1 (en) 2007-07-30 2009-02-04 Santhera Pharmaceuticals (Schweiz) AG Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
EP2243779A4 (en) 2007-12-19 2011-04-20 Dainippon Sumitomo Pharma Co HETEROCYCLIC BICYCLIC DERIVATIVE
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
KR101353857B1 (ko) 2008-08-22 2014-01-21 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
WO2010059393A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Serotonin receptor modulators
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011014795A2 (en) 2009-07-30 2011-02-03 Irm Llc Compounds and compositions as syk kinase inhibitors
RU2580320C2 (ru) 2009-08-18 2016-04-10 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
EP2550263A4 (en) 2010-03-23 2013-07-24 Univ Johns Hopkins COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
PH12012502046A1 (en) 2010-04-14 2017-07-26 Array Biopharma Inc 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
WO2012020813A1 (ja) 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
KR101827048B1 (ko) 2010-08-27 2018-02-07 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
WO2012045089A2 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the treatment of allergic diseases
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
WO2012097177A2 (en) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
BR112013017943A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores receptores do tipo toll
WO2012097479A1 (en) 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
EP3266464A3 (en) 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
HUE036220T2 (hu) 2011-05-18 2018-06-28 Janssen Sciences Ireland Uc Kinazolin származékok vírusfertõzések és további betegségek kezelésére
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
DE102011080362A1 (de) 2011-08-03 2013-02-07 Robert Bosch Gmbh Elektrisches Kontaktelement mit Rastlanze für ein Steckergehäuse
KR101979042B1 (ko) 2011-08-04 2019-05-15 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
CN104024257A (zh) 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
AU2012323399A1 (en) 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
BR122022001235B1 (pt) 2011-11-29 2023-04-11 Ono Pharmaceutical Co., Ltd Cristal de cloridrato derivado de purinona
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
PL2807165T3 (pl) * 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
EA039373B1 (ru) 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
RU2622034C2 (ru) 2012-02-09 2017-06-09 Мерк Патент Гмбх ПРОИЗВОДНЫЕ ФУРО[3,2-В]- И ТИЕНО[3,2-В]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TBK1 И IKKε
WO2013130660A1 (en) 2012-02-28 2013-09-06 Amgen Inc. Amides as pim inhibitors
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
MX2014011749A (es) 2012-03-31 2015-01-22 Hoffmann La Roche 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b.
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
NZ724503A (en) 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
BR112015002524B1 (pt) 2012-08-10 2021-11-03 Janssen Sciences Ireland Uc Derivados de alquilpirimidina, composição farmacêutica que os compreende e uso dos mesmos
SG11201501360TA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK1208465A1 (en) 2012-08-28 2016-03-04 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6113285B2 (ja) 2012-09-10 2017-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン
WO2014047624A1 (en) 2012-09-24 2014-03-27 Gilead Sciences, Inc. Anti-ddr1 antibodies
CN104981458B (zh) 2012-10-02 2017-07-21 吉利德科学公司 组蛋白去甲基化酶抑制剂
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
KR101268466B1 (ko) 2012-11-12 2013-06-04 유병수 사축형 윈드 터빈
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
HUE037312T2 (hu) 2012-12-19 2018-08-28 Celgene Quanticel Res Inc Hiszton demetiláz inhibitorok
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2935246B1 (en) 2012-12-21 2018-07-25 Gilead Calistoga LLC Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
EP2941426B1 (en) 2012-12-21 2018-06-13 Gilead Calistoga LLC Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
EP2940019B1 (en) 2012-12-27 2018-03-28 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
CN103114087B (zh) 2013-01-24 2015-05-06 北京大学第三医院 一种rna及其在心血管系统疾病中的应用
CN103110932B (zh) 2013-01-24 2015-08-19 北京大学第三医院 一种hip-55的新用途
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
SG10201707027SA (en) 2013-02-27 2017-09-28 Epitherapeutics Aps Inhibitors of histone demethylases
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9133166B2 (en) 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
RS56561B1 (sr) 2013-03-15 2018-02-28 Quanticel Pharmaceuticals Inc Inhibitori histon demetilaze
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
RS57999B1 (sr) 2013-05-17 2019-01-31 Janssen Sciences Ireland Uc Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b
WO2014184328A1 (en) 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TWI644909B (zh) 2013-06-14 2018-12-21 基利科學股份有限公司 磷脂酸肌醇３－激酶抑制劑
WO2014202493A1 (en) 2013-06-19 2014-12-24 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives
ES2774749T3 (es) 2013-07-25 2020-07-22 Janssen Sciences Ireland Unlimited Co Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EP3027601B1 (en) 2013-07-31 2017-10-25 Gilead Sciences, Inc. Syk inhibitors
CA2920377A1 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
EA029901B1 (ru) 2013-09-04 2018-05-31 Бристол-Майерс Сквибб Компани Соединения для применения в качестве иммуномодуляторов
CU24362B1 (es) 2013-09-06 2018-10-04 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
HRP20181251T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori
AU2014316686B2 (en) 2013-09-06 2018-11-22 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
JP6366721B2 (ja) 2013-09-11 2018-08-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
EP3057948B1 (en) 2013-10-14 2018-03-14 Eisai R&D Management Co., Ltd. Selectively substituted quinoline derivatives
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
EA201690979A1 (ru) 2013-11-14 2016-08-31 Новира Терапьютикс, Инк. Производные азепана и способы лечения инфекций гепатита в
US9801880B2 (en) 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
CA2933466A1 (en) 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015113990A1 (en) 2014-01-30 2015-08-06 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
AU2015214404B2 (en) 2014-02-04 2020-10-01 Incyte Corporation Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
EP3114144A1 (en) 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
SG11201607794QA (en) 2014-03-19 2016-10-28 Boehringer Ingelheim Int Heteroaryl syk inhibitors
JP6377245B2 (ja) 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｓｍｏ阻害剤としてのキノリン誘導体
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN112877291A (zh) 2014-04-10 2021-06-01 西雅图儿童医院 (Dba西雅图儿童研究所) 基因修饰的t细胞产品、其制备方法和用途
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PL3134402T3 (pl) 2014-04-22 2020-11-02 F.Hoffmann-La Roche Ag Związki 4-amino-imidazochinolinowe
WO2015168279A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
EP3143020B1 (en) 2014-05-13 2019-08-21 F. Hoffmann-La Roche AG Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US20170182003A1 (en) 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
CA2951259A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016019232A1 (en) 2014-08-01 2016-02-04 John Vasilakos Methods and therapeutic combinations for treating tumors
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
LT3190113T (lt) 2014-08-15 2021-08-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
EP3398948A3 (en) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
KR20170040805A (ko) 2014-08-27 2017-04-13 길리애드 사이언시즈, 인코포레이티드 히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
US9884866B2 (en) 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
CA2960778C (en) 2014-09-11 2023-03-07 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
US20170298443A1 (en) 2014-09-25 2017-10-19 Moffitt Genetics Corporation Prognostic tumor biomarkers
CN107912040B (zh) 2014-10-10 2021-04-06 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
JP2017531655A (ja) 2014-10-11 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染性疾患の処置に使用するための化合物
LT3212629T (lt) 2014-10-31 2019-01-10 Genoscience Pharma Sas Pakeistieji 2,4 diamino-chinolinai, kaip nauji priešvėžiniai agentai
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
JP2017538678A (ja) 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
JP2017533925A (ja) 2014-11-13 2017-11-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
KR102557560B1 (ko) 2014-12-08 2023-07-20 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물
US20160166613A1 (en) 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
WO2016096778A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Benzazepine sulfonamide compounds
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
WO2016109684A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106625A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CN107208102B (zh) 2015-01-27 2021-07-06 豪夫迈·罗氏有限公司 重组hbv cccdna、其产生方法及其用途
EA032530B1 (ru) 2015-01-28 2019-06-28 Байер Фарма Акциенгезельшафт 4h-пирроло[3,2-c]пиридин-4-оновые производные
WO2016126460A2 (en) 2015-02-06 2016-08-11 Proteq Technologies Llc Electrochromic devices
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN104878084B (zh) 2015-03-04 2018-01-09 上海市杨浦区中心医院 检测奥沙利铂对于结直肠癌有效性的试剂盒
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
PE20171456A1 (es) 2015-03-06 2017-10-06 Hoffmann La Roche Compuestos de dicarboxamida de benzazepinas
BR112017019307A2 (pt) 2015-03-10 2018-05-02 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
WO2016145252A1 (en) 2015-03-10 2016-09-15 The Trustees Of Princeton University Shmt inhibitors
CA2979145A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
MX384444B (es) 2015-03-10 2025-03-14 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
WO2016142886A2 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016161145A1 (en) 2015-03-31 2016-10-06 Dana-Farber Cancer Institute, Inc. Stk4 inhibitors for treatment of hematologic malignancies
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016161196A1 (en) 2015-04-03 2016-10-06 Mirna Therapeutics, Inc. Microrna-34 immunotherapy
WO2016164428A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016162867A1 (en) 2015-04-08 2016-10-13 Efranat Ltd. Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
CN107531693B (zh) 2015-04-10 2021-07-06 百济神州有限公司 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶
US10273228B2 (en) 2015-04-17 2019-04-30 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
CA2982984C (en) 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
AU2016257772B2 (en) 2015-05-01 2022-06-02 Griffith University Diagnostic methods
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
EP4001283A1 (en) 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
WO2016195982A2 (en) 2015-06-01 2016-12-08 The Penn State Research Foundation Hepatitis b virus capsid assembly
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6898868B2 (ja) 2015-06-25 2021-07-07 ユニバーシティー ヘルス ネットワーク Ｈｐｋ１阻害剤およびそれを用いる方法
US20160376864A1 (en) 2015-06-29 2016-12-29 Cameron International Corporation Apparatus and method for distributing fluids to a wellbore
GB201511477D0 (en) 2015-06-30 2015-08-12 Redx Pharma Plc Antiviral compounds
EP3317289B1 (en) 2015-06-30 2021-10-27 F. Hoffmann-La Roche AG Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112017028456A2 (pt) 2015-07-02 2018-08-28 Glaxosmithkline Ip Dev Ltd composto, e, método de prevenção e/ou tratamento de hiv
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
CN107849037B (zh) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
JP6506880B2 (ja) 2015-07-27 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
EP3328858B1 (en) 2015-07-28 2019-05-15 H. Hoffnabb-La Roche Ag Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
EP3328407A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination of pd-1 antagonist with an egfr inhibitor
EP3332027A1 (en) 2015-08-06 2018-06-13 Stichting Katholieke Universiteit Method for the prediction of progression of bladder cancer
MX386992B (es) 2015-08-10 2025-03-19 Merck Sharp & Dohme Llc Compuestos antivirales de fosfodiamida de éster de beta-aminoácido.
MA42608A (fr) 2015-08-13 2018-06-20 Merck Sharp & Dohme Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
EP3337481B1 (en) 2015-08-21 2020-11-11 The University of Kansas Quinoline-2-amine derivatives as human tlr8-selective agonists for increasing immune response
WO2017038909A1 (en) 2015-08-28 2017-03-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EP3344622B1 (en) 2015-08-31 2021-07-07 3M Innovative Properties Company Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
MX2018003353A (es) 2015-09-17 2018-09-17 Novartis Ag Terapias con celulas cart con una eficacia mejorada.
WO2017047769A1 (ja) 2015-09-17 2017-03-23 国立大学法人富山大学 トール様受容体７またはトール様受容体９の活性化阻害剤
JP6893501B2 (ja) 2015-09-17 2021-06-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
FR3041639B1 (fr) 2015-09-30 2019-01-25 Les Laboratoires Servier NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
EP3360554B1 (en) 2015-10-05 2021-07-28 FUJIFILM Toyama Chemical Co., Ltd. Anti-hepatitis b virus agent
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
CN108430503A (zh) 2015-10-28 2018-08-21 艾杜罗生物科技公司 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法
WO2017079669A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
US10676478B2 (en) 2015-11-05 2020-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
SG11201804170RA (en) 2015-12-17 2018-06-28 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
ITUB20159605A1 (it) 2015-12-17 2017-06-17 Alda S R L Kinase and ubiquitin ligase inhibitors and uses thereof
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
BR112018013914A2 (pt) 2016-01-08 2018-12-11 Univ California polipeptídeos heterodiméricos condicionalmente ativos e métodos de utilização deste
AU2017219216B2 (en) 2016-02-19 2019-12-19 Novartis Ag Tetracyclic pyridone compounds as antivirals
WO2017151732A1 (en) 2016-03-02 2017-09-08 Beth Israel Deaconess Medical Center Technology Venture Office, Br2 Therapeutic targets for lin-28-expressing cancers
WO2017156454A1 (en) 2016-03-10 2017-09-14 The Regents Of The University Of California Anti-cancer and splce modulating compounds and methods
EP3429596B1 (en) 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
US10662177B2 (en) 2016-03-21 2020-05-26 Council Of Scientific & Industrial Research Blocking toll-like receptor 9 signaling with small molecule antagonist
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
KR102571679B1 (ko) 2016-04-15 2023-08-29 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
LT3453707T (lt) 2016-05-06 2022-03-10 Shanghai De Novo Pharmatech Co., Ltd. Benzazepino darinys, gamybos būdas, farmacinė kompozicija ir jos naudojimas
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
JP7022702B2 (ja) 2016-05-23 2022-02-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP6918838B2 (ja) 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
WO2017202798A1 (en) 2016-05-26 2017-11-30 F. Hoffmann-La Roche Ag Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
MX2018015315A (es) 2016-06-10 2019-04-25 Enanta Pharm Inc Agentes antivirales contra la hepatitis b.
EP3468963B1 (en) 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Dihydropyrimidinyl benzazepine carboxamide compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
JP6570776B2 (ja) 2016-06-20 2019-09-04 テグ−キョンプク メディカル イノベーション ファウンデーション 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
WO2017219931A1 (zh) 2016-06-22 2017-12-28 四川科伦博泰生物医药股份有限公司 二氢蝶啶酮类衍生物、其制备方法及其用途
KR101789430B1 (ko) 2016-06-28 2017-10-25 동국대학교 산학협력단 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
ES2817426T3 (es) 2016-06-29 2021-04-07 Novira Therapeutics Inc Derivados de oxadiazepinona y su uso en el tratamiento de infecciones por hepatitis B
MA45550A (fr) 2016-06-29 2019-05-08 Novira Therapeutics Inc Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
WO2018001952A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
EP3478686B1 (en) 2016-06-29 2020-04-15 H. Hoffnabb-La Roche Ag Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR102468272B1 (ko) 2016-06-30 2022-11-18 삼성전자주식회사 음향 출력 장치 및 그 제어 방법
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
JP6301402B2 (ja) 2016-07-01 2018-03-28 日新製鋼株式会社 フェライト系ステンレス鋼板およびその製造方法
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP7168551B2 (ja) 2016-07-08 2022-11-09 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JP7034133B2 (ja) 2016-07-14 2022-03-11 エフ．ホフマン－ラ ロシュ アーゲー 感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物
WO2018011100A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7051804B2 (ja) 2016-07-14 2022-04-11 エフ．ホフマン－ラ ロシュ アーゲー 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物
EP3490987B1 (en) 2016-07-29 2022-09-21 Guangzhou Lupeng Pharmaceutical Company Ltd. Novel therapeutic agents for the treatment of hbv infection
WO2018019297A1 (zh) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
CA3031675A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
CN109195602B (zh) 2016-08-03 2022-01-07 上海齐鲁制药研究中心有限公司 用作免疫调节剂的对称或半对称化合物
WO2018036941A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
WO2018038877A1 (en) 2016-08-26 2018-03-01 3M Innovative Properties Company FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
WO2018043747A1 (ja) 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
BE1024865B1 (fr) 2016-09-07 2018-07-31 Glaxosmithkline Biologicals Sa Derives d'imidazoquinoleine
WO2018045911A1 (zh) 2016-09-09 2018-03-15 浙江海正药业股份有限公司 二氢嘧啶类化合物及其制备方法和用途
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
TWI771319B (zh) 2016-09-09 2022-07-21 美商英塞特公司 吡唑并吡啶化合物及其用途
CN115215886B (zh) 2016-09-09 2024-10-11 诺华股份有限公司 作为内体Toll样受体抑制剂的化合物及组合物
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018065360A1 (de) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
MX2019004561A (es) 2016-10-20 2019-08-05 Aurigene Discovery Tech Ltd Inhibidores dobles del supresor de inmunoglobulina del dominio v de la activacion de linfocitos t (vista) y las vias de muerte programada 1 (pd-1).
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
WO2018078149A1 (en) 2016-10-31 2018-05-03 F. Hoffmann-La Roche Ag Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EP3535280B1 (en) 2016-11-07 2022-03-16 Bristol-Myers Squibb Company Immunomodulators
US11084818B2 (en) 2016-11-11 2021-08-10 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
US11370794B2 (en) 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
EP3538097A1 (en) 2016-11-11 2019-09-18 Gilead Sciences, Inc. Methods of treating liver disease
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
ES2886973T3 (es) 2016-11-28 2021-12-21 Jiangsu Hengrui Medicine Co Derivado pirazolo-heteroarilo, método de preparación y uso médico del mismo
WO2018102366A1 (en) 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200113924A1 (en) 2016-12-20 2020-04-16 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
MA47094A (fr) 2016-12-22 2021-05-26 Idenix Pharmaceuticals Llc Promédicaments d'ester aliphatique antiviral de ténofovir
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018152220A1 (en) * 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN110402248B (zh) 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
US10407424B2 (en) 2017-03-30 2019-09-10 Genentech, Inc. Naphthyridines as inhibitors of HPK1
AU2018272986A1 (en) 2017-05-26 2019-12-12 Ichnos Sciences SA Novel inhibitors of MAP4K1
US20200246347A1 (en) 2017-06-13 2020-08-06 Bayer Pharma Aktiengesellschaft Substituted Pyrrolopyridine-Derivatives
CA3066859A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2018228923A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US12098172B2 (en) 2017-07-31 2024-09-24 The Johns Hopkins University Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
CN109721620B (zh) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
MX2020004179A (es) 2017-10-31 2020-08-03 Eisai R&D Man Co Ltd Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
KR102808367B1 (ko) 2017-11-06 2025-05-14 브리스톨-마이어스 스큅 컴퍼니 Hpk1 억제제로서 유용한 이소푸라논 화합물
ES2969284T3 (es) 2018-01-19 2024-05-17 Medshine Discovery Inc Derivado de piridona-pirimidina que actúa como inhibidor de la muteína krasg12c
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US20210139484A1 (en) 2018-04-11 2021-05-13 Gossamer Bio Services, Inc. Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2019206049A1 (en) 2018-04-25 2019-10-31 Zhuhai Yufan Biotechnologies Co., Ltd Hpk1 inhibitors, preparation method and application thereof
CN108823307B (zh) 2018-05-17 2020-10-30 浙江大学 Pd‐l1剪接体b作为指导抗pd‐l1/pd1免疫治疗的用药的标志物的应用
TWI848954B (zh) 2018-06-13 2024-07-21 英屬開曼群島商百濟神州有限公司 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
CN112601584A (zh) 2018-07-24 2021-04-02 豪夫迈·罗氏有限公司 异喹啉化合物及其用途
JP7386842B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ナフチリジン化合物およびその使用
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7486478B2 (ja) 2018-09-19 2024-05-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト スピロ環状２，３－ジヒドロ－７－アザインドール化合物およびその使用
JP7433304B2 (ja) 2018-09-30 2024-02-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト シンノリン化合物および癌などのｈｐｋ１依存性障害の治療
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
CN113166062A (zh) 2018-10-03 2021-07-23 豪夫迈·罗氏有限公司 8-氨基异喹啉化合物及其用途
WO2020070331A1 (en) 2018-10-05 2020-04-09 Ichnos Sciences S.A. Indolinone compounds for use as map4k1 inhibitors
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CN113166139A (zh) 2018-11-22 2021-07-23 百济神州有限公司 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2020163382A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114007614A (zh) 2019-02-04 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP2022519311A (ja) 2019-02-05 2022-03-22 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
EP3920919A4 (en) 2019-02-05 2023-03-29 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020188467A1 (zh) 2019-03-15 2020-09-24 杭州英创医药科技有限公司 作为激酶抑制剂的稠合三环化合物
US12492194B2 (en) 2019-03-26 2025-12-09 Janssen Pharmaceutica Nv HPK1 inhibitors
TW202102500A (zh) 2019-03-26 2021-01-16 比利時商健生藥品公司 二環ｈｐｋ１抑制劑
AU2020271530B2 (en) 2019-04-09 2026-02-05 Envisagenics, Inc. Cancer-specific molecules and methods of use thereof
KR20220012230A (ko) 2019-04-24 2022-02-03 스톡 테라퓨틱스, 인크. 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
US20220242870A1 (en) 2019-05-17 2022-08-04 Voronoi Inc. Heterocycle-fused pyrimidine derivative and use thereof
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
KR20220044495A (ko) 2019-07-04 2022-04-08 치루 레고르 테라퓨틱스 인코포레이티드 Hpk1 억제제 및 그의 용도
WO2021004547A1 (en) 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
TW202116753A (zh) 2019-07-11 2021-05-01 大陸商南京征祥醫藥有限公司 以噌啉作為hpk1的抑制劑
US12459958B2 (en) 2019-07-17 2025-11-04 Beone Medicines I Gmbh Tricyclic compounds as HPK1 inhibitor and the use thereof
PE20221419A1 (es) 2019-08-06 2022-09-20 Incyte Corp Formas solidas de un inhibidor de hpk1
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20220265864A1 (en) 2019-08-15 2022-08-25 Lifesplice Pharma Llc Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
CN114341127B (zh) 2019-08-21 2024-12-17 百济神州有限公司 作为hpk1抑制剂的氨基吡嗪化合物及其用途
US20220348917A1 (en) 2019-09-04 2022-11-03 Exicure Operating Company Liposomal spherical nucleic acid (sna) constructs for splice modulation
CN119874700A (zh) 2019-09-13 2025-04-25 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN112552293A (zh) 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
CN115279771B (zh) 2020-01-15 2025-03-21 缆图药品公司 Map4k1抑制剂
CN113336747A (zh) 2020-03-03 2021-09-03 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用
US20230130909A1 (en) 2020-04-20 2023-04-27 Wigen Biomedicine Technology (shanghai) Co., Ltd. Hpk1 inhibitor, preparation method therefor and use thereof
IL297838A (en) 2020-05-01 2023-01-01 Pfizer Azalactam compounds as hpk1 inhibitors
CN118930560A (zh) 2020-05-06 2024-11-12 新锐思生物制药股份有限公司 造血祖细胞激酶的双功能降解剂及其治疗用途
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
TW202208375A (zh) 2020-05-11 2022-03-01 加拿大健康網路大學 ４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
CN113797202B (zh) 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN113845531B (zh) 2020-06-28 2025-06-27 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
US20230399327A1 (en) 2020-10-28 2023-12-14 Adlai Nortye Biopharma Co., Ltd. High activity hpk1 kinase inhibitor
CN114437058A (zh) 2020-10-30 2022-05-06 珠海宇繁生物科技有限责任公司 氘代hpk1激酶抑制剂及其制备方法和应用
CN114437074A (zh) 2020-11-03 2022-05-06 北京伯汇生物技术有限公司 一种化合物、含该化合物的药物组合物及其用途
WO2022098806A1 (en) 2020-11-09 2022-05-12 Merck Sharp & Dohme Corp. 7-phenyl substituted 2-aminoquinazoline inhibitors of hpk1
WO2022098809A1 (en) 2020-11-09 2022-05-12 Merck Sharp & Dohme Corp. Diaminopyrimidine carboxamide inhibitors of hpk1
WO2022098807A1 (en) 2020-11-09 2022-05-12 Merck Sharp & Dohme Corp. 7-azole substituted 2-aminoquinazoline inhibitors of hpk1
CN116438172A (zh) 2020-11-13 2023-07-14 南京红云生物科技有限公司 Hpk1激酶调节剂、其制备方法与应用
WO2022107919A1 (ko) 2020-11-19 2022-05-27 주식회사 보로노이 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN114516857A (zh) 2020-11-20 2022-05-20 深圳智药信息科技有限公司 Hpk1抑制剂及其用途
US20240002394A1 (en) 2020-11-24 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Deuterium-modified thienopyridone compound
KR20220085735A (ko) 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
CN114685489B (zh) 2020-12-31 2025-03-07 南京再明医药有限公司 多取代含氮杂环类化合物及其应用
CN114685490B (zh) 2020-12-31 2025-03-28 南京再明医药有限公司 吡咯并吡啶类化合物及其应用
CN114805330B (zh) 2021-01-22 2026-03-10 苏州信诺维医药科技股份有限公司 Hpk1抑制剂、其制备方法、药物组合物及其应用
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors
CN114907374B (zh) 2021-02-07 2026-03-10 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
CN114907375A (zh) 2021-02-07 2022-08-16 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
WO2022166920A1 (zh) 2021-02-08 2022-08-11 杭州中美华东制药有限公司 一种吡咯并哒嗪类化合物及其制备方法和用途
CN116848113A (zh) 2021-02-10 2023-10-03 南京再明医药有限公司 作为hpk1抑制剂的双环类化合物及其应用
CN114907377A (zh) 2021-02-10 2022-08-16 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
US12252488B2 (en) 2021-02-12 2025-03-18 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2022184152A1 (zh) 2021-03-03 2022-09-09 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022188735A1 (en) 2021-03-08 2022-09-15 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as hpk1 inhibitors
TW202246284A (zh) 2021-03-10 2022-12-01 大陸商山東軒竹醫藥科技有限公司 三并環類hpk1抑制劑及其用途
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
CN113861188B (zh) 2021-08-23 2023-02-28 杭州医学院 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用
CN114315796B (zh) 2021-12-30 2024-03-26 中国药科大学 用作hpk1激酶抑制剂的化合物及其制备方法和应用
CN114767676B (zh) 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用
CN114853730B (zh) 2022-05-27 2024-03-26 中国药科大学 用作hpk1激酶抑制剂的化合物及其制备方法和应用
CN114940683B (zh) 2022-07-26 2023-01-17 轩竹(北京)医药科技有限公司 Hpk1抑制剂及其用途

Also Published As

Publication number Publication date
TW202033522A (zh) 2020-09-16
US20240287061A1 (en) 2024-08-29
DOP2021000079A (es) 2021-06-15
DOP2023000252A (es) 2024-02-15
JP7460644B2 (ja) 2024-04-02
IL282535B1 (en) 2024-01-01
PT3873903T (pt) 2024-05-16
CL2021001132A1 (es) 2021-11-26
JP2022509533A (ja) 2022-01-20
EP4671244A1 (en) 2025-12-31
EP3873903A1 (en) 2021-09-08
MY205142A (en) 2024-10-03
CR20210215A (es) 2021-06-17
CA3117556A1 (en) 2020-05-07
SI3873903T1 (sl) 2024-06-28
LT3873903T (lt) 2024-05-10
FI3873903T3 (fi) 2024-03-26
IL282535A (en) 2021-06-30
ZA202304921B (en) 2025-01-29
PL3873903T3 (pl) 2024-05-20
EP4371987A1 (en) 2024-05-22
UA126619C2 (uk) 2022-11-02
ES3052607T3 (en) 2026-01-12
MX2021005047A (es) 2021-09-08
AU2022218506B2 (en) 2024-06-13
US20210115037A1 (en) 2021-04-22
CN113227089A (zh) 2021-08-06
SG11202103839UA (en) 2021-05-28
IL282535B2 (en) 2024-05-01
NZ775025A (en) 2024-10-25
AU2022218506A1 (en) 2022-09-08
US20220213091A1 (en) 2022-07-07
US12258346B2 (en) 2025-03-25
AU2019372046A1 (en) 2021-05-20
PE20211655A1 (es) 2021-08-24
CN113227089B (zh) 2024-07-05
PH12021551019A1 (en) 2022-02-21
EP3873903B1 (en) 2024-01-24
KR20210086685A (ko) 2021-07-08
US11897878B2 (en) 2024-02-13
WO2020092621A1 (en) 2020-05-07
EP4371987B1 (en) 2025-09-17
EP4371987B9 (en) 2025-11-26
US11203591B2 (en) 2021-12-21
TWI721623B (zh) 2021-03-11
BR112021008255A2 (pt) 2021-08-03
EP4371987C0 (en) 2025-09-17
ES2979163T3 (es) 2024-09-24
AU2019372046B2 (en) 2022-05-26
ZA202403426B (en) 2025-10-29
CO2021005711A2 (es) 2021-05-20
AU2024203579A1 (en) 2024-06-20
KR102650496B1 (ko) 2024-03-26
AU2024203579B2 (en) 2026-03-05
TW202136260A (zh) 2021-10-01
HRP20251388T1 (hr) 2026-01-30
JP2024026363A (ja) 2024-02-28
HUE066750T2 (hu) 2024-09-28
DK3873903T3 (da) 2024-04-02
HRP20240541T1 (hr) 2024-07-05

Similar Documents

Publication Publication Date Title
SG11202103839UA (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
GB201705971D0 (en) Inhibitor compounds
ZA201708244B (en) Thioether compounds as nitrification inhibitors
IL282659A (en) Heterocyclic compounds as bet inhibitors
GB201513481D0 (en) Inhibitor compounds
GB201914860D0 (en) Inhibitor compounds
GB201819126D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
GB201905328D0 (en) Inhibitor compounds
GB201507036D0 (en) Crystalline enzyme inhibitor compound
GB201819136D0 (en) Inhibitor compounds
GB201905318D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds
GB201806131D0 (en) Inhibitor compounds
GB201720145D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
HK40017164A (en) Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
GB201621619D0 (en) Inhibitor compounds
GB201613945D0 (en) Compounds useful as kinase inhibitors